Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York

December 4, 2018 at 8:30 AM EST

DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018, in New York City. Theravance Biopharma management and R&D teams will provide an overview of the Company's research and development strategy, plus clinical programs and emerging research projects in therapeutic areas such as inflammatory intestinal diseases, autonomic disorders, severe asthma, lung transplant rejection, idiopathic pulmonary fibrosis, and diabetic macular edema.

(PRNewsfoto/Theravance Biopharma, Inc.)

Those interested in attending the event may RSVP here.

Those interested in listening live via the internet may access the webcast here, or by visiting Theravance Biopharma's website at, under the Investor Relations section, Presentations and Events. Please go to the website 15 minutes prior to the start of the event to register, download, and install any necessary audio software. An audio replay will also be available following the event.

About Theravance Biopharma

Theravance Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.

In our relentless pursuit of this objective, we strive to apply insight and innovation at each stage of our business, including research, development and commercialization, and utilize both internal capabilities and those of partners around the world. Our research efforts are focused in the areas of inflammation and immunology. Our research goal is to design localized medicines that target diseased tissues, without systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing localized medicines for the lungs to treat respiratory disease. The first potential medicine to emerge from our research focus on immunology and localized treatments is an oral, gut-selective pan-Janus kinase (JAK) inhibitor, currently in development to treat a range of inflammatory intestinal diseases. Our pipeline of internally discovered product candidates will continue to evolve with the goal of creating transformational medicines to address the significant needs of patients.

In addition, we have an economic interest in future payments that may be made by Glaxo Group or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including Trelegy Ellipta.

For more information, please visit

THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact Information:

Alexander Dobbin
Head of Investor Relations

Tim Brons
Vida Strategic Partners (media)


Cision View original content to download multimedia:

SOURCE Theravance Biopharma, Inc.

Shareholder Tools